{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:12:58Z","timestamp":1778278378058,"version":"3.51.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"C","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and importance:<\/jats:title>\n                    <jats:p>Refractory immune thrombocytopenic purpura (ITP) is a rare but serious condition causing significant morbidity and mortality due to inadequate response to standard treatments, resulting in persistent thrombocytopenia and increased bleeding risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>An 18-year-old female patient, diagnosed with ITP two years prior following excessive vaginal bleeding and fatigue, was initially treated with oral prednisolone for two months and discharged in improved condition. Eighteen months after treatment cessation, she presented with recurrent excessive vaginal bleeding, intermittent bilateral nasal bleeding, skin rash, blurred vision, fatigue, tinnitus, vertigo, and intermittent headaches (one-month duration). Following a one-month admission during which she proved unresponsive to steroids, she received rituximab 500 mg IV weekly for four weeks, along with supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical discussion:<\/jats:title>\n                    <jats:p>Refractory ITP in conjunction with COVID-19 is a rare and serious condition associated with significant morbidity and mortality, and a low survival rate. Effective, coordinated medical and surgical management, along with comprehensive rehabilitation from COVID-19, are crucial for improving outcomes in this severe condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Refractory ITP is a challenging and rare condition that can result in significant health complications, economic burdens, and a reduced quality of life for those affected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijscr.2024.110704","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T12:13:19Z","timestamp":1732882399000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A case report of refractory immune thrombocytopenia: Challenges in choice of therapies in resource limiting center"],"prefix":"10.1097","volume":"126","author":[{"given":"Addisu Assfaw","family":"Ayen","sequence":"first","affiliation":[{"name":"Assistant Professor of Internal Medicine, College of Health Science, Deberetabor University, Debretabor, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desalegne Nigatu","family":"Chanie","sequence":"additional","affiliation":[{"name":"Assistant Professor of Internal Medicine, Gastroenterologist, College of Medicine and Health Science, Bahirdar University, Bahirdar, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meseret Adugna","family":"Mamuye","sequence":"additional","affiliation":[{"name":"Assistant Professor of Internal Medicine, College of Medicine and Health Science, Bahirdar University, Bahirdar, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wali Ahmed","family":"Nur","sequence":"additional","affiliation":[{"name":"Bachelor Degree on Radiologic Technology, Master of Public Health, Jigjiga, Somalia, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musse Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Assistant Professor of Surgery, College of Medicine and Health Science, Jigjiga, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atalel Fentahun","family":"Awedew","sequence":"additional","affiliation":[{"name":"Assistant Professor of Surgery, College of Health Science, Deberetabor University, Debretabor, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"10","key":"R1-62-20260508","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"R2-62-20260508","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero RS","year":"2009","journal-title":"Blood"},{"issue":"7","key":"R3-62-20260508","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"issue":"5","key":"R4-62-20260508","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/JS9.0000000000000373","article-title":"The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines","volume":"109","author":"Sohrabi","year":"2023","journal-title":"Int. J. Surg. Lond. Engl."},{"issue":"1","key":"R5-62-20260508","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2141.2008.07275.x","article-title":"Refractory immune thrombocytopenic purpura: current strategies for investigation and management","volume":"43","author":"Psaila","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"22","key":"R6-62-20260508","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"issue":"23","key":"R7-62-20260508","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"25","key":"R8-62-20260508","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry","volume":"1","author":"Arnold","year":"2017","journal-title":"Blood Adv."},{"issue":"3","key":"R9-62-20260508","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25379","article-title":"Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data","volume":"94","author":"Mitta","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"12","key":"R10-62-20260508","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"6","key":"R12-62-20260508","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"issue":"25","key":"R13-62-20260508","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"issue":"2","key":"R14-62-20260508","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00464-018-6321-y","article-title":"Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort","volume":"33","author":"Tastaldi","year":"2019","journal-title":"Surg. Endosc."},{"issue":"6","key":"R15-62-20260508","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"R16-62-20260508","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminhematol.2014.10.006","article-title":"Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists","volume":"52","author":"Rodeghiero","year":"2015","journal-title":"Semin. Hematol."},{"issue":"2","key":"R17-62-20260508","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/bjh.16426","article-title":"Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children","volume":"189","author":"Gudbrandsdottir","year":"2020","journal-title":"Br. J. Haematol."},{"key":"R18-62-20260508","article-title":"A case of primary refractory immune thrombocytopenia: challenges in choice of therapies","author":"Tuncer","year":"2018","journal-title":"Hindawi"},{"issue":"6","key":"R19-62-20260508","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"Pavord","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261224014858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261224014858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.ijscr.2024.110704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:01:36Z","timestamp":1778277696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1016\/j.ijscr.2024.110704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"C","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2024.110704","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}